MapLight CFO Terminated for Cause Eight Months After IPO
Management crisis
Company Background
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on central nervous system disorders. It has no revenue and depends entirely on its balance sheet, which stood at $395.2 million in cash, cash equivalents, and investments at March 31, 2026 — a figure management says is sufficient to fund operations through 2027. The net loss for Q1 2026 was $60.7 million.
The company went public on October 28, 2025, raising gross proceeds of $296.3 million through its IPO and a concurrent private placement. It has two programs in the final stretch of Phase 2 testing: ML-007C-MA (brand name ZEPHYR trial, schizophrenia) and ML-004 (IRIS trial, autism spectrum disorder). Both trials completed enrollment in early 2026, with topline results guided for by mid-August 2026.
The clinical pipeline is the company's primary asset. MPLT carries no debt of consequence and has structured operations around delivering those two readouts — making leadership continuity in the run-up to those results particularly relevant to investors.
What Was Disclosed
Vishwas Setia was terminated as Chief Financial Officer on June 18, 2026, effective immediately, "following a review of a human resources violation." The company stated his separation was "wholly unrelated to the Company's financial or operating results, internal controls or clinical programs, or any concerns or disagreements regarding the Company's financial or reporting practices." Setia is not entitled to any severance. Under a Separation Agreement signed the same day, he will receive continued health coverage for himself and his dependents under COBRA for up to three months. The full terms of that agreement will be filed as an exhibit to the company's quarterly report for the period ending June 30, 2026.